scholarly journals microRNA-20b-5p overexpression combing Pembrolizumab potentiates cancer cells to radiation therapy via repressing programmed death-ligand 1

Bioengineered ◽  
2021 ◽  
Vol 13 (1) ◽  
pp. 917-929
Author(s):  
Kexin Jiang ◽  
Huawei Zou
Phytomedicine ◽  
2021 ◽  
Vol 80 ◽  
pp. 153394
Author(s):  
Luo-Wei Yuan ◽  
Xiao-Ming Jiang ◽  
Yu-Lian Xu ◽  
Mu-Yang Huang ◽  
Yu-Chi Chen ◽  
...  

2017 ◽  
Author(s):  
Christina M. Maher ◽  
Jeffrey D. Thomas ◽  
Charles G. Longen ◽  
Derick A. Haas ◽  
Halley M. Oyer ◽  
...  

Molecules ◽  
2021 ◽  
Vol 26 (17) ◽  
pp. 5345
Author(s):  
Benjawan Wudtiwai ◽  
Anupong Makeudom ◽  
Suttichai Krisanaprakornkit ◽  
Peraphan Pothacharoen ◽  
Prachya Kongtawelert

Up-regulated expression of programmed death-ligand 1 (PD-L1) by interferon-gamma (IFN-γ) has been associated with promotion of cancer cell survival and tumor cell escape from anti-tumor immunity. Therefore, a blockade of PD-L1 expression can potentially be used as a molecular target for cancer therapy. The aim of this study was to investigate whether suppression of IFN-γ induced PD-L1 expression in two oral cancer cell lines, HN6 and HN15, by hesperidin effectively decreased cell proliferation and migration. Further, our objective was to elucidate the involvement of the signal transducer and activator of transcription 1 (STAT1) and STAT3 in the inhibition of induced PD-L1 expression by hesperidin. Our findings indicate that IFN-γ induced expression of PD-L1 protein in HN6 and HN15 via phosphorylation of STAT1 and STAT3 and that hesperidin significantly reduced that induction through suppression of phosphorylated STAT1 and STAT3 in both cell lines. Moreover, hesperidin also significantly decreased the viability, proliferation, migration, and invasion of both cell lines. In conclusion, hesperidin exerted anticancer effects against oral cancer cells through the suppression of PD-L1 expression via inactivation of the STAT1 and STAT3 signaling molecules. The findings of this study support the use of hesperidin as a potential adjunctive treatment for oral cancer.


Sign in / Sign up

Export Citation Format

Share Document